BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433-440. [PMID: 23318480 DOI: 10.1038/ajg.2012.430] [Cited by in Crossref: 145] [Cited by in F6Publishing: 122] [Article Influence: 18.1] [Reference Citation Analysis]
Number Citing Articles
1 Wuebbolt D, Nguyen V, D'Souza R, Wyne A. Devic syndrome and pregnancy: A case series. Obstet Med 2018;11:171-7. [PMID: 30574178 DOI: 10.1177/1753495X18758868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver. 2016;10:177-203. [PMID: 26934884 DOI: 10.5009/gnl15352] [Cited by in Crossref: 70] [Cited by in F6Publishing: 50] [Article Influence: 14.0] [Reference Citation Analysis]
3 Kanis SL, Modderman S, Escher JC, Erler N, Beukers R, de Boer N, Bodelier A, Depla ACTM, Dijkstra G, van Dijk ARM, Gilissen L, Hoentjen F, Jansen JM, Kuyvenhoven J, Mahmmod N, Mallant-Hent RC, van der Meulen-de Jong AE, Noruzi A, Oldenburg B, Oostenbrug LE, Ter Borg PCJ, Pierik M, Romberg-Camps M, Thijs W, West R, de Lima A, van der Woude CJ; Initiative on Crohns and Colitis (ICC). Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut 2021;70:1266-74. [PMID: 33046558 DOI: 10.1136/gutjnl-2019-319129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Bell SJ, Flanagan EK. Updates in the management of inflammatory bowel disease during pregnancy. Medical Journal of Australia 2019;210:276-80. [DOI: 10.5694/mja2.50062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 McConnell RA, Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am 2016;45:285-301. [PMID: 27261899 DOI: 10.1016/j.gtc.2016.02.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
6 Vinnitskaya EV, Sandler YG, Bakulin IG, Parfenov AI, Ilchenko LY, Nikitin IG, Bueverov AO, Lopatkina TN, Ignatova ТМ, Syutkin VY, Raikhelson KL, Khomeriki SG, Gudkova RB. Important problems in the diagnosis and treatment of autoimmune hepatitis (based on the Russian consensus 2017). Ter Arkh 2018;90:12-8. [PMID: 30701766 DOI: 10.26442/terarkh201890212-18] [Reference Citation Analysis]
7 Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol 2014;26:347-53. [PMID: 24625373 DOI: 10.1097/BOR.0000000000000048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
8 Lee S, Seow CH, Adhikari K, Metcalfe A. Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. Aliment Pharmacol Ther 2020;51:544-52. [DOI: 10.1111/apt.15596] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ; Crohn’s Colitis Foundation Clinical Research Alliance. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology 2021;160:1131-9. [PMID: 33227283 DOI: 10.1053/j.gastro.2020.11.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
10 Winter R, Nørgård BM, Friedman S. Treatment of the Pregnant Patient with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:733-744. [PMID: 26658216 DOI: 10.1097/MIB.0000000000000625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
11 Kanis S, Kreijne J, van der Woude C. Commentary on “ Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis”. Hum Exp Toxicol 2017;36:993-4. [DOI: 10.1177/0960327116689719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges 2021;19:1092-115. [PMID: 34288477 DOI: 10.1111/ddg.14507] [Reference Citation Analysis]
13 Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, Quantin C, Bardou M. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). American Journal of Gastroenterology 2018;113:1669-77. [DOI: 10.1038/s41395-018-0176-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 26.3] [Reference Citation Analysis]
14 Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response. Dig Dis Sci 2016;61:1622-7. [DOI: 10.1007/s10620-015-3992-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
15 Mahadevan U, Matro R. Care of the Pregnant Patient With Inflammatory Bowel Disease. Obstetrics & Gynecology 2015;126:401-12. [DOI: 10.1097/aog.0000000000000978] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
16 Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, Dalekos GN, Muratori L. Review article: autoimmune hepatitis -- current management and challenges. Aliment Pharmacol Ther. 2013;38:887-913. [PMID: 24010812 DOI: 10.1111/apt.12470] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 12.4] [Reference Citation Analysis]
17 van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. Gut 2014;63:1014-23. [DOI: 10.1136/gutjnl-2013-305418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
18 Huang VW, Habal FM. From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol 2014;20:3495-506. [PMID: 24707132 DOI: 10.3748/wjg.v20.i13.3495] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
19 Uchino M, Ikeuchi H, Matsuoka H, Bando T, Hirose K, Hirata A, Chohno T, Sasaki H, Yokoyama Y, Nakamura S, Nakamura Y, Takesue Y. Surgery for Severe Ulcerative Colitis during Pregnancy: Report of Two Cases. Case Rep Gastroenterol 2015;9:74-80. [PMID: 25960728 DOI: 10.1159/000381141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Mozaffari S, Abdolghaffari A, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis. Hum Exp Toxicol 2015;34:445-59. [DOI: 10.1177/0960327114550882] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
21 Pottinger E, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH. Exposure to biological therapies during conception and pregnancy: a systematic review. Br J Dermatol 2018;178:95-102. [PMID: 28718898 DOI: 10.1111/bjd.15802] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
22 Nørgård BM, Magnussen B, Fedder J, de Silva PS, Wehberg S, Friedman S. The Risk of Elective Abortion in Women With Crohn's Disease and Ulcerative Colitis: A Nationwide Cohort Study. Inflamm Bowel Dis 2019;25:561-7. [PMID: 30107577 DOI: 10.1093/ibd/izy263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810. [PMID: 26888948 DOI: 10.1136/annrheumdis-2015-208840] [Cited by in Crossref: 445] [Cited by in F6Publishing: 325] [Article Influence: 89.0] [Reference Citation Analysis]
24 Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to Infliximab During Pregnancy: Post-Marketing Experience. Drug Saf 2020;43:147-61. [PMID: 31677004 DOI: 10.1007/s40264-019-00881-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
25 Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun 2017;76:38-52. [PMID: 27913060 DOI: 10.1016/j.jaut.2016.11.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
26 Tandon P, Govardhanam V, Leung K, Maxwell C, Huang V. Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:320-33. [DOI: 10.1111/apt.15587] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
27 Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174. [PMID: 23902720 DOI: 10.1186/1741-7015-11-174] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
28 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität. J Dtsch Dermatol Ges 2021;19:1092-117. [PMID: 34288473 DOI: 10.1111/ddg.14507_g] [Reference Citation Analysis]
29 Rahim MN, Long L, Penna L, Williamson C, Kametas NA, Nicolaides KH, Heneghan MA. Pregnancy in Liver Transplantation. Liver Transpl 2020;26:564-81. [PMID: 31950556 DOI: 10.1002/lt.25717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
30 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
31 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 178] [Article Influence: 37.3] [Reference Citation Analysis]
32 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1011-8. [PMID: 28346274 DOI: 10.1097/MIB.0000000000001102] [Cited by in Crossref: 57] [Cited by in F6Publishing: 10] [Article Influence: 19.0] [Reference Citation Analysis]
33 Plavšić I, Stimac T, Hauser G. Crohn's disease in women. Int J Womens Health 2013;5:681-8. [PMID: 24204175 DOI: 10.2147/IJWH.S38083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Valer P, Algaba A, Santos D, Fuentes ME, Nieto E, Gisbert JP, López P, Quintanilla E, García-alonso FJ, Guerra I, Páez Á, Bermejo F. Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:1144-53. [DOI: 10.1097/mib.0000000000001081] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 4.3] [Reference Citation Analysis]
36 Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol 2021;12:214-24. [PMID: 33912333 DOI: 10.1136/flgastro-2019-101371] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Adar T, Grisaru-granovsky S, Ben Ya’acov A, Goldin E, Bar-gil Shitrit A. Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective. Dig Dis Sci 2015;60:2581-9. [DOI: 10.1007/s10620-015-3683-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
38 Gubatan J, Nielsen OH, Levitte S, Juhl CB, Maxwell C, Streett SE, Habtezion A. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2021;116:243-53. [PMID: 33110017 DOI: 10.14309/ajg.0000000000000910] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
39 Tsao NW, Rebic N, Lynd LD, De Vera MA. Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2020;59:1808-17. [PMID: 32118278 DOI: 10.1093/rheumatology/keaa064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
40 Chaparro M, Gisbert JP. Surgery for Crohn's disease during pregnancy: a difficult decision. United European Gastroenterol J 2020;8:633-4. [PMID: 32628893 DOI: 10.1177/2050640620928181] [Reference Citation Analysis]
41 Gaidos JK, Kane SV. Managing IBD Therapies in Pregnancy. Curr Treat Options Gastroenterol 2017;15:71-83. [PMID: 28181180 DOI: 10.1007/s11938-017-0123-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
42 Friedman S, McElrath TF, Wolf JL. Management of fertility and pregnancy in women with inflammatory bowel disease: a practical guide. Inflamm Bowel Dis. 2013;19:2937-2948. [PMID: 23945187 DOI: 10.1097/mib.0b013e3182a0ea6f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
43 Kammerlander H, Nielsen J, Knudsen T, Kjeldsen J, Friedman S, Nørgård BM. Anti–TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight: . Inflammatory Bowel Diseases 2017;23:1916-23. [DOI: 10.1097/mib.0000000000001234] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
44 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
45 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Kim SC, Hernandez-Diaz S. Editorial: Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases. Arthritis Rheumatol. 2014;66:246-249. [PMID: 24504795 DOI: 10.1002/art.38258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
47 Colla L, Diena D, Rossetti M, Manzione AM, Marozio L, Benedetto C, Biancone L. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol 2018;31:361-83. [DOI: 10.1007/s40620-018-0477-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
48 Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-salinas CA, Álvarez Nemegyei J, Fraga Mouret A, Orozco Alcalá J, Salazar Páramo M, Cruz Reyes CV, Andrade Ortega L, Vera Lastra OL, Mendoza Pinto C, Sánchez González A, Cruz Cruz PDR, Morales Hernández S, Portela Hernández M, Pérez Cristóbal M, Medina García G, Hernández Romero N, Velarde Ochoa MDC, Navarro Zarza JE, Portillo Díaz V, Vargas Guerrero A, Goycochea Robles MV, García Figueroa JL, Barreira Mercado E, Amigo Castañeda MC. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatología Clínica 2015;11:305-15. [DOI: 10.1016/j.reuma.2014.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
49 Hendy P, Chadwick G, Hart A. Republished curriculum based clinical review: IBD: reproductive health, pregnancy and lactation. Postgrad Med J 2015;91:230-5. [DOI: 10.1136/postgradmedj-2014-100430rep] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Cao RH, Grimm MC. Pregnancy and medications in inflammatory bowel disease. Obstet Med 2021;14:4-11. [PMID: 33995565 DOI: 10.1177/1753495X20919214] [Reference Citation Analysis]
51 Mao EJ, Mahadevan U. The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy. Am J Gastroenterol 2018;113:1590-1. [PMID: 30337704 DOI: 10.1038/s41395-018-0254-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
52 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 De Felice KM, Kane SV. Inflammatory bowel disease in women of reproductive age. Expert Rev Gastroenterol Hepatol 2014;8:417-25. [PMID: 24580047 DOI: 10.1586/17474124.2014.893822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
54 Ateka-Barrutia O, Khamashta MA. The challenge of pregnancy for patients with SLE. Lupus 2013;22:1295-308. [PMID: 24098002 DOI: 10.1177/0961203313504637] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
55 Gaidos JK, Kane SV. Overcoming challenges of treating inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2016;12:871-8. [PMID: 26981845 DOI: 10.1586/1744666X.2016.1166958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Veerisetty SS, Eschete SO, Uhlhorn AP, De Felice KM. Women's Health in Inflammatory Bowel Disease. Am J Med Sci 2018;356:227-33. [PMID: 30286817 DOI: 10.1016/j.amjms.2018.05.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Kanis SL, van der Woude CJ. Proper Use of Inflammatory Bowel Disease Drugs during Pregnancy. Dig Dis 2016;34 Suppl 1:61-6. [PMID: 27548630 DOI: 10.1159/000447377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Gisbert JP, Chaparro M. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. Drugs 2020;80:1085-100. [PMID: 32562207 DOI: 10.1007/s40265-020-01346-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
59 Kattah MG, Milush JM, Burt T, McCabe RP Jr, Whang MI, Ma A, Mahadevan U. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol 2018;9:143. [PMID: 29618720 DOI: 10.1038/s41424-018-0018-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
60 Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, Peyrin-biroulet L, Marteau P, Cadiot G, Laharie D, Boureille A, De Vos M, Savoye G, Rahier J, Carbonnel F, Bonaz B, Colombel J, Bouhnik Y. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:363-73. [DOI: 10.1111/apt.12833] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
61 Narula N, Al-dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2014;20:1862-9. [DOI: 10.1097/mib.0000000000000092] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
62 Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther 2014;40:991-1008. [PMID: 25200000 DOI: 10.1111/apt.12949] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
63 McConnell RA, Mahadevan U. Use of Immunomodulators and Biologics Before, During, and After Pregnancy. Inflamm Bowel Dis. 2016;22:213-223. [PMID: 26444103 DOI: 10.1097/mib.0000000000000596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
64 Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951-958. [PMID: 23834232 DOI: 10.3109/00365521.2013.812141] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
65 Chaparro M, Donday MG, Abad-Santos F, Martín de Carpi FJ, Maciá-Martínez MÁ, Montero D, Acosta D, Brenes Y, Gisbert JP. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therap Adv Gastroenterol 2021;14:17562848211018097. [PMID: 34158835 DOI: 10.1177/17562848211018097] [Reference Citation Analysis]
66 Nuñez F P, Quera R, Sepúlveda E, Simian D, Pizarro G, Lubascher J, Flores L, Ibañez P, Figueroa C, Kronberg U. Pregnancy in Inflammatory Bowel Disease: Experience of a Chilean cohort. Gastroenterol Hepatol 2021;44:277-85. [PMID: 33745519 DOI: 10.1016/j.gastrohep.2020.08.005] [Reference Citation Analysis]
67 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
68 Mahadevan U, Mcconnell RA, Chambers CD. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. Gastroenterology 2017;152:451-462.e2. [DOI: 10.1053/j.gastro.2016.10.013] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
69 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31281-7. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
70 Park EJ, Kim H, Jung SM, Sung YK, Baek HJ, Lee J. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean J Intern Med 2020;35:41-59. [PMID: 31935319 DOI: 10.3904/kjim.2019.411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
71 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
72 Cortes X, Borrás-Blasco J, Antequera B, Fernandez-Martinez S, Casterá E, Martin S, Molés JR. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther 2017;42:234-6. [PMID: 28004853 DOI: 10.1111/jcpt.12492] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
73 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
74 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Raval M, Choy MC, De Cruz P. Salvage therapy for acute severe ulcerative colitis during pregnancy. BMJ Case Rep 2018;2018:bcr-2017-223540. [PMID: 29884712 DOI: 10.1136/bcr-2017-223540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Rao VL, Micic D, Kim KE. Primary Care Evaluation and Management of Gastroenterologic Issues in Women. Obstet Gynecol Clin North Am 2016;43:347-66. [PMID: 27212096 DOI: 10.1016/j.ogc.2016.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11:116-127. [PMID: 23897285 DOI: 10.1038/nrgastro.2013.135] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
78 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 15.5] [Reference Citation Analysis]
79 Shihab Z, Yeomans ND, De Cruz P. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.J Crohns Colitis. 2016;10:979-988. [PMID: 26755733 DOI: 10.1093/ecco-jcc/jjv234] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
80 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World J Gastroenterol. 2016;22:9257-9278. [PMID: 27895415 DOI: 10.3748/wjg.v22.i42.9257] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
82 Chaudrey KH, Kane SV. Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. Curr Treat Options Gastro 2015;13:77-89. [DOI: 10.1007/s11938-014-0037-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
83 Bröms G, Kieler H, Ekbom A, Gissler M, Hellgren K, Lahesmaa-Korpinen AM, Pedersen L, Schmitt-Egenolf M, Sørensen HT, Granath F. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020;29:316-27. [PMID: 32020767 DOI: 10.1002/pds.4930] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
84 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
85 Park E, Kim H, Jung SM, Sung Y, Baek HJ, Lee J. The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. J Rheum Dis 2020;27:4. [DOI: 10.4078/jrd.2020.27.1.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
86 Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in pregnancy: current perspectives. Clin Exp Gastroenterol 2016;9:325-35. [PMID: 27789969 DOI: 10.2147/CEG.S96676] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
87 Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J, Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-smith G, Lawrance IC, Andrews JM, Ellard K, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016;151:110-9. [DOI: 10.1053/j.gastro.2016.04.002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 138] [Article Influence: 33.2] [Reference Citation Analysis]
88 van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124. [PMID: 25602023 DOI: 10.1093/ecco-jcc/jju006] [Cited by in Crossref: 220] [Cited by in F6Publishing: 179] [Article Influence: 44.0] [Reference Citation Analysis]
89 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 10.5] [Reference Citation Analysis]
90 Larsen MD, Friedman S, Magnussen B, Nørgård BM. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception. American Journal of Gastroenterology 2016;111:1608-13. [DOI: 10.1038/ajg.2016.405] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
91 Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193-207. [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
92 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
93 Morvillo C, Vinci K, Hedenschoug L, Mancini L, Mize C, Tugg K, Stein S. Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease: A Review for Nurses. Gastroenterology Nursing 2020;43:E159-71. [DOI: 10.1097/sga.0000000000000523] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21. [PMID: 29357999 DOI: 10.1016/j.gastrohep.2017.11.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
95 Ng SW, Mahadevan U. My treatment approach to management of the pregnant patient with inflammatory bowel disease. Mayo Clin Proc. 2014;89:355-360. [PMID: 24582194 DOI: 10.1016/j.mayocp.2013.11.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
96 Hosseini-Carroll P, Mutyala M, Seth A, Nageeb S, Soliman D, Boktor M, Sheth A, Chapman J, Morris J, Jordan P. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. World J Gastrointest Pharmacol Ther. 2015;6:156-171. [PMID: 26558150 DOI: 10.4292/wjgpt.v6.i4.156] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
97 Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: Safety issues. World J Gastrointest Pharmacol Ther. 2014;5:63-76. [PMID: 24868487 DOI: 10.4292/wjgpt.v5.i2.63] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
98 Thomas C, Monteil-Ganiere C, Mirallié S, Hémont C, Dert C, Léger A, Joyau C, Caldari D, Audrain M. A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. J Crohns Colitis 2018;12:258-61. [PMID: 28961694 DOI: 10.1093/ecco-jcc/jjx123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
99 Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Current Opinion in Rheumatology 2014;26:334-40. [DOI: 10.1097/bor.0000000000000054] [Cited by in Crossref: 48] [Cited by in F6Publishing: 10] [Article Influence: 6.9] [Reference Citation Analysis]
100 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
101 de Boer NK, de Meij T, van Bodegraven AA. Thiopurines during pregnancy in inflammatory bowel disease: is there a risk for the (unborn) child? Expert Review of Gastroenterology & Hepatology 2014;7:669-71. [DOI: 10.1586/17474124.2013.841541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
102 Poturoglu S, Ormeci AC, Duman AE. Treatment of pregnant women with a diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016;7:490-502. [PMID: 27867682 DOI: 10.4292/wjgpt.v7.i4.490] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
103 Leung KK, Tandon P, Govardhanam V, Maxwell C, Huang V. The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:550-62. [PMID: 32469057 DOI: 10.1093/ibd/izaa122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
104 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 5.7] [Reference Citation Analysis]
105 Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016;111:176-194; quiz 196. [PMID: 26832651 DOI: 10.1038/ajg.2015.430] [Cited by in Crossref: 100] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
106 Hendy P, Chadwick G, Hart A. IBD: reproductive health, pregnancy and lactation. Frontline Gastroenterol 2015;6:38-43. [PMID: 28839793 DOI: 10.1136/flgastro-2014-100430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
107 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021;193:E1129-36. [PMID: 34312166 DOI: 10.1503/cmaj.202391] [Reference Citation Analysis]
108 Kanis SL, de Lima-karagiannis A, de Boer NK, van der Woude CJ. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. Clinical Gastroenterology and Hepatology 2017;15:1232-1241.e1. [DOI: 10.1016/j.cgh.2017.02.041] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
109 Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol 2018;113:1678-88. [PMID: 30022113 DOI: 10.1038/s41395-018-0202-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
110 Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol. 2016;64:933-945. [PMID: 26658682 DOI: 10.1016/j.jhep.2015.11.030] [Cited by in Crossref: 92] [Cited by in F6Publishing: 48] [Article Influence: 15.3] [Reference Citation Analysis]
111 Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opinion on Drug Safety 2014;13:1749-62. [DOI: 10.1517/14740338.2014.959489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
112 Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171:485-491. [PMID: 24749725 DOI: 10.1111/bjd.13060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
113 Czaja AJ. Diagnosis and management of autoimmune hepatitis. Clin Liver Dis 2015;19:57-79. [PMID: 25454297 DOI: 10.1016/j.cld.2014.09.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
114 . ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation. Obstetrics & Gynecology 2019;133:e287-95. [DOI: 10.1097/aog.0000000000003176] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
115 Johansen CB, Jimenez-Solem E, Haerskjold A, Sand FL, Thomsen SF. The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review. Int J Mol Sci 2018;19:E1349. [PMID: 29751529 DOI: 10.3390/ijms19051349] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
116 de Lima A, Kanis SL, Escher JC, van der Woude CJ. Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero. J Crohns Colitis 2018;12:948-53. [PMID: 29726943 DOI: 10.1093/ecco-jcc/jjy053] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
117 Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 2019;18:357-67. [DOI: 10.1080/14740338.2019.1612874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
118 Bennett A, Mamunes A, Kim M, Duley C, Garrett A, Annis K, Wagnon J, Dalal R, Scoville E, Beaulieu D, Schwartz D, Horst S. The Importance of Monitoring the Postpartum Period in Moderate to Severe Crohn's Disease. Inflamm Bowel Dis 2021:izab104. [PMID: 33999196 DOI: 10.1093/ibd/izab104] [Reference Citation Analysis]
119 Mammen A, Korelitz BI. The Management of Severe Ulcerative Colitis During the Third Trimester of Pregnancy. Journal of Clinical Gastroenterology 2015;49:257-8. [DOI: 10.1097/mcg.0000000000000221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN. Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Can J Gastroenterol Hepatol 2016;2016:6193275. [PMID: 27725926 DOI: 10.1155/2016/6193275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
121 Deepak P, Stobaugh DJ. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:1035-43. [DOI: 10.1111/apt.12936] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
122 Simsek M, Lambalk CB, Wilschut JA, Mulder CJJ, de Boer NKH. The associations of thiopurines with male fertility and paternally exposed offspring: a systematic review and meta-analysis. Hum Reprod Update 2018;24:192-206. [PMID: 29190351 DOI: 10.1093/humupd/dmx034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]